PubMed Trending Research Digest — August 31, 2026

Automated digest · 98 articles · 15 research areas · August 31, 2026

Overview

A dominant thread across this week’s papers is precision risk management—using biomarkers, trajectories, and “personalized add-ons” to anticipate clinical deterioration and tailor therapy. In cardiovascular care, multiple studies focus on how serial or pathway-specific biomarkers (e.g., hs-troponin patterns, adrenomedullin system components) can forecast downstream outcomes such as cardiogenic shock or heart failure, while pragmatic trials and stepped-wedge implementations test whether faster, scalable strategies (digital outreach for statin refills; shorter troponin pathways in the ED) can improve real-world outcomes. In parallel, several studies extend precision thinking beyond the heart: CHIP-driven somatic mutations and epigenetic clocks/diet-specific methylation signatures are explored as systemic predictors of cardiometabolic risk and disease progression.

Another major theme is mechanism-linked therapeutics emerging from multi-omics and cell-state biology. Across cancer, studies connect metabolic rewiring (cholesterol/lipid rafts in cisplatin resistance; SREBP–lipogenesis/ferroptosis resistance; m6A readers driving metabolic survival) and cell-death pathways (IFI27–GSDME pyroptosis; RIPK1 necroptosis to potentiate radio-immunotherapy) to actionable vulnerabilities. In non-oncology biology, bile acids and bile-acid–mitochondria signaling appear repeatedly as mechanistic bridges between organ systems (cholestatic liver disease biology; bile acid–mitochondria axis review; microbiome–metabolite links to delirium and long COVID), while neurodegeneration papers emphasize extracellular matrix stiffness, axon–glia dysfunction, and immune/inflammatory drivers as early determinants.

Finally, the digest highlights a translational push toward safer, more durable interventions: gene therapy safety frameworks for AAV toxicities, attempts to optimize long-term dosing (e.g., reduced-frequency ART; tofacitinib dose reduction in ulcerative colitis), and refined antithrombotic regimens after procedures (TAVR leaflet thrombosis imaging outcomes; AF/PCI anticoagulant combinations). Together, these studies reflect a broader shift from single-mechanism interventions toward integrated, biomarker-guided, and mechanism-validated strategies—aiming to improve both efficacy and safety across diverse patient populations.

---

Cardiovascular risk prediction & biomarkers

Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer’s disease progression.

This multi-cohort longitudinal study of 2117 individuals evaluated whether baseline plasma phosphorylated tau217 (p-tau217) thresholds—calibrated against amyloid-β PET (Aβ-PET)—remain stable and predict Alzheimer’s disease (AD) progression over time. Baseline-defined cutoffs showed high, sustained accuracy (86–95%) for Aβ-PET positivity up to 5 years, and most p-tau217-positive participants stayed stable (93–98%) while the intermediate group progressed to positivity more often (44 [truncated]). These findings support plasma p-tau217 as a clinically useful, longitudinally robust biomarker for staging AD amyloid pathology and forecasting disease trajectory.

Lan G, Liao W, Jiang M et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

DLST Succinylation-Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma.

This study investigated how succinylation of the mitochondrial metabolic enzyme dihydrolipoamide S-succinyltransferase (DLST) drives malignant progression and cuproptosis resistance in lung adenocarcinoma (LUAD), using succinylation proteomics and mechanistic perturbations. DLST lysine 409 (K409) succinylation was increased in LUAD and was catalyzed by carnitine palmitoyltransferase 1A (CPT1A), with DLST K409 succinylation promoting metabolic remodeling and resistance to cuproptosis (details truncated). The work identifies a CPT1A→DLST K409 succinylation axis as a potential therapeutic target to overcome cuproptosis resistance in LUAD.

Li X, Zhou P, Peng X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Extracellular matrix remodeling upregulates hippocampal neurogenic niche stiffness and impairs neurogenesis in Alzheimer’s disease.

This study examined whether extracellular matrix (ECM) remodeling increases hippocampal neurogenic niche stiffness and impairs adult neurogenesis in Alzheimer’s disease using 5×FAD mice and human AD patient ECM/proteomics. Using atomic force microscopy to measure stiffness, the authors found that ECM changes upregulated stiffness in the dentate gyrus subgranular zone (SGZ), and experimentally increasing stiffness in wild-type mice impaired neurogenesis while reducing stiffness in 5×FAD mice improved neurogenic lineage gene expression (gene analysis via siRNA; truncated). These results link AD-associated ECM remodeling to biophysical niche dysfunction and suggest stiffness modulation as a strategy to preserve hippocampal neurogenesis.

Sun W, Yang B, Zheng H et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk.

This narrative review studied polyendocrine metabolic ovarian syndrome (PMOS)—the 2026 re-framing of polycystic ovary syndrome (PCOS)—focusing on endocrine/metabolic dysfunction and cardiovascular risk in women of reproductive age. It highlights insulin resistance and compensatory hyperinsulinemia as central mechanisms connecting reproductive, psychological/dermatologic, and cardiometabolic consequences, emphasizing PMOS as a lifelong multisystem disorder (truncated). The clinical significance is improved recognition and risk stratification of cardiovascular disease in PMOS to guide earlier, more comprehensive management beyond reproductive symptoms.

Forslund M, Melin J, Joham AE et al. · Journal of internal medicine · (2026) · View on PubMed ↗

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression.

This study investigated how a CD9+ germinal center B (GC-B) cell subset regulates germinal center regression in adenoid hypertrophy (AH) using single-cell RNA sequencing (scRNA-seq), flow cytometry, and mass cytometry (CyToF). A CD9+ GC-B subset was identified and shown to be regulated by FOXP1, with CD9+ B cells inducing T follicular helper (Tfh) cell apoptosis to drive GC regression termination (apoptosis pathway details truncated). The findings suggest CD9/FOXP1-controlled GC-B cell apoptosis as a mechanistic lever for controlling pathological germinal center persistence in AH.

Liao W, Song L, Xu M et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.

This mechanistic cancer study examined the role of the m6A RNA reader YTHDC1 in triple-negative breast cancer (TNBC), focusing on how it rewires glucose and glutamate metabolism to survive lethal metabolic stress. YTHDC1 was specifically overexpressed in TNBC and correlated with poor prognosis, and it promoted metabolic adaptability in an m6A-dependent manner by stabilizing GLUT3 mRNA to sustain glucose uptake and NADPH production while reducing ATF4 mRNA stability to suppress SLC7A11-mediated cystine/glutamate exchange (truncated). The work positions YTHDC1 as a potential therapeutic target to disrupt TNBC metabolic resilience.

Lai ZH, Wang Y, Li NN et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.

This review studied the expanding use of chimeric antigen receptor (CAR)-engineered cell therapies beyond cancer, covering evidence for autoimmune, inflammatory, and fibrotic diseases. It reports that early clinical data suggest CD19- or BCMA-directed CAR-T cells can induce deep B-cell/plasma-cell depletion and sustained remission in selected refractory autoimmune patients, while CAR-based fibrosis treatment remains largely preclinical (truncated). The significance is that it maps where clinical maturity exists versus where rigorous comparative efficacy, durability, and long-term safety data are still needed.

Xu PJ, Zhang ZJ, Jin J et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer.

This study investigated how alanyl tRNA synthetase 1 (AARS1) drives aggressive, recurrent bladder cancer by coupling epigenetic/lactylation signaling to glycolysis. AARS1 was upregulated in bladder cancer tissues, enriched in muscle-invasive and recurrent tumors, and functionally promoted proliferation, EMT, invasion, apoptosis resistance, tumor growth, and lung colonization, while mechanistically enhancing PI3K pathway output, glycolytic flux, and lactate production via AARS1-mediated H3K27 lactylation (truncated). These findings identify AARS1 and H3K27 lactylation–linked glycolytic rewiring as potential targets to prevent recurrence and progression in bladder cancer.

Yuan Q, Song T, He Y et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Phenotypic clustering and ABC pathway adherence in patients with atrial fibrillation at high risk of bleeding and stroke: Insights from three global registries.

This analysis studied clinical phenotypes and outcomes in atrial fibrillation (AF) patients at high risk of both bleeding and stroke using data from three global registries. Using hierarchical clustering, the authors assessed how adherence to the integrated care based on the ABC pathway related to one-year net adverse clinical events (NACE) in patients with HAS-BLED ≥3 and CHA2DS2-VASc ≥2 (truncated). The significance is improved phenotype-aware evaluation of ABC pathway implementation to reduce combined thrombotic and hemorrhagic risk in high-risk AF populations.

Askarinejad A, Bucci T, Tartaglia E et al. · European journal of internal medicine · (2026) · View on PubMed ↗

Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.

This study evaluated ivonescimab combined with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC) in the UCGI 52–GRACIE trial. The trial is designed as a multicenter, two-arm study testing ivonescimab plus FOLFOX as first-line (Arm-1) and ivonescimab plus paclitaxel/irinotecan or FOLFIRI after progression (Arm-2), regardless of PD-L1/HER2/CLDN-18.2 actionable target status (truncated). The clinical significance is determining whether ivonescimab can improve efficacy and safety outcomes across lines of therapy in GC/EGJC beyond biomarker-restricted strategies.

Raimbourg J, Botsen D, Pernot S et al. · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · (2026) · View on PubMed ↗

Serial high-sensitivity troponin-T and risk of heart failure in individuals with suspected acute coronary syndrome.

This Danish nationwide registry study examined whether serial high-sensitivity cardiac troponin-T (hs-TnT) patterns in individuals presenting with suspected acute coronary syndrome (ACS) predicted subsequent heart failure, excluding those with known heart failure. Participants with rising or persistently elevated hs-TnT (and greater peak hs-TnT levels) had a higher risk of later heart failure than those with normal or falling patterns. These findings support using serial hs-TnT trajectories for risk stratification after suspected ACS to identify patients who may benefit from closer follow-up or preventive strategies.

Erichsen PA, Afzal M, Byrne C et al. · International journal of cardiology · (2026) · View on PubMed ↗

Cardiovascular Prevention among Healthcare Professionals: the ESC Congress Cardiovascular Health Check 2025.

This study assessed cardiovascular risk profiles, awareness, treatment use, target achievement, and subclinical atherosclerosis (via carotid ultrasonography) among 1366 healthcare professionals attending the ESC Congress Cardiovascular Health Check 2025, comparing those without established ASCVD to age- and sex-matched groups. The key finding was that healthcare professionals still had measurable gaps in cardiovascular risk management, with substantial proportions not meeting recommended targets and evidence of subclinical atherosclerosis in a subgroup. These results highlight that even clinicians who deliver prevention care may benefit from structured cardiovascular screening and treatment optimization programs.

Wenzl FA, Wang Y, Mass V et al. · European heart journal · (2026) · View on PubMed ↗

Autophagic degradation of RAB8A promotes ferroptosis through dysregulation of TFRC-mediated iron uptake.

The authors investigated how selective autophagy regulates ferroptosis in cancer cells by identifying RAB8A as an ATG5/ATG7-dependent autophagic substrate under ferroptotic stress. They found that ferroptotic stimuli trigger RNF126-mediated polyubiquitination of RAB8A followed by SQSTM1-mediated autophagic degradation, and that loss of RAB8A sensitizes cells to ferroptosis while a degradation-resistant mutant (RAB8AQ67L) suppresses this effect. This mechanistic link between RAB8A autophagic turnover and TFRC-mediated iron uptake provides a potential target pathway to modulate ferroptosis sensitivity in oncology.

Li J, Zhou Q, Liu J et al. · Autophagy · (2026) · View on PubMed ↗

Early SOX9 Activation Primes Hippo-YAP/TAZ Rewiring During Glioblastoma Stemness Acquisition.

This study used single-cell RNA sequencing, pseudotime reconstruction, spatial transcriptomics, and functional in vitro/in vivo assays to define the temporal role of SOX9 during glioblastoma stemness acquisition. SOX9 expression peaked during the early astrocyte-to-malignant transition and then declined as malignant states stabilized, showing inverse coupling with the upstream Hippo kinase module and phase-dependent association with YAP/TAZ transcriptional programs. The findings suggest early SOX9 activation primes Hippo–YAP/TAZ rewiring that supports glioblastoma stemness, identifying a potential timing-specific vulnerability for therapeutic intervention.

Mijiti M, Li Y, Maimaiti A et al. · Journal of cellular and molecular medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Effect of In-Hospital Initiation of Dapagliflozin on Decongestion in Patients Hospitalized for Heart Failure: An Analysis of the DAPA ACT HF-TIMI 68 Trial.

In the NOTION-4 randomized trial, patients without an indication for oral anticoagulation shortly after successful TAVR were assigned to lifelong single antiplatelet therapy (SAPT) or 3 months of a direct oral anticoagulant (DOAC) followed by lifelong SAPT (DOAC-3m), with outcomes focused on subclinical leaflet thrombosis measured by CT as hypoattenuated leaflet thickening (HALT). The key finding was that short-term DOAC therapy reduced HALT compared with lifelong SAPT, supporting DOACs as more effective at preventing subclinical leaflet thrombosis after TAVR. Clinically, this informs post-TAVR antithrombotic strategy to mitigate imaging-defined thrombotic risk even in patients without baseline oral anticoagulation indications.

Small AM, Patel SM, Thomas C et al. · JACC. Heart failure · (2026) · View on PubMed ↗ · Free PDF ↗

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.

This analysis of the HELIOS-B trial evaluated whether the effect of vutrisiran (an RNA interference therapeutic that suppresses hepatic transthyretin production) differed by baseline use of tafamidis in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The key finding was that vutrisiran’s treatment effects were consistent across tafamidis baseline subgroups rather than being substantially diminished or amplified by concomitant tafamidis use. This supports the scientific rationale that combining transthyretin stabilization (tafamidis) with transthyretin gene silencing (vutrisiran) may be clinically feasible, with efficacy not strongly dependent on starting tafamidis.

Hamatani Y, Claggett BL, Cuddy SAM et al. · Journal of the American College of Cardiology · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.

Using data from 654 randomized ATTR-CM patients in HELIOS-B, this study characterized concomitant therapy patterns and tested whether disease-modifying or heart failure therapies modified the efficacy of vutrisiran. The key finding was that concomitant background therapies did not meaningfully alter vutrisiran’s relative treatment effect on outcomes, indicating robustness of efficacy across real-world medication use patterns. This strengthens confidence that vutrisiran can provide benefit regardless of concurrent ATTR-CM and heart failure treatments.

Abovich A, Fontana M, Claggett B et al. · Journal of the American College of Cardiology · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

SIRT1 Silences L1 Retrotransposons by Stabilizing Heterochromatin-Modifying Complexes.

This meta-analysis synthesized phase 3 randomized, placebo-controlled outcome trials of TTR gene-silencing therapies in transthyretin amyloid cardiomyopathy (ATTR-CM), with attention to how effects varied by baseline TTR stabilizer use (e.g., tafamidis). The key finding was that gene-silencing therapies reduced adverse outcomes overall and showed consistent benefit across baseline stabilizer strata despite differences in trial design and background therapy. These results support the general effectiveness of hepatic TTR gene-silencing approaches and help clinicians interpret expected benefit when patients are already receiving TTR stabilizers.

Wang X, Li T, Tang H et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.

This study examined how the sirtuin SIRT1 regulates cellular senescence-associated LINE-1 (L1) retrotransposition by stabilizing heterochromatin-modifying complexes. The key finding was that SIRT1 suppresses L1 retrotransposition and thereby reduces L1-driven transcriptional activation and downstream interferon responses associated with senescence. These results connect SIRT1 activity to epigenetic control of L1 elements, suggesting a mechanistic route by which SIRT1 may influence aging and age-related inflammatory disease.

Gillmore JD, Hamatani Y, Fontana M et al. · JAMA · (2026) · View on PubMed ↗

COVID-19 Vaccination and Risk of Post-COVID-19 Cardiovascular Disease: A Population-Based Cohort and Target Trial Emulation Study.

This population-based cohort study and target trial emulation used linked administrative health data from 2,391,456 adults in Victoria, Australia (2019–2025) to evaluate how COVID-19 vaccination timing relative to SARS-CoV-2 infection affected post-COVID cardiovascular disease risk. The key finding was that vaccination was associated with lower risk of major adverse cardiovascular events and other post-COVID cardiovascular outcomes, and that infection prevention likely contributed substantially to the observed risk reduction. The study provides evidence that vaccination may confer longer-term cardiovascular protection after infection, informing public health and clinical risk management strategies.

Seboka BT, Magliano DJ, Marwick TH et al. · European heart journal. Quality of care & clinical outcomes · (2026) · View on PubMed ↗

Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis.

This individual patient data network meta-analysis studied antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI), pooling randomized trial data and analyzing outcomes with Cox proportional hazards models stratified by trial. Compared with vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), direct oral anticoagulants (DOACs) combined with a P2Y12 inhibitor reduced bleeding without increasing ischemic risk. These findings strengthen evidence for DOAC-based regimens after PCI in AF patients and improve generalizability for clinical decision-making on balancing bleeding versus ischemic outcomes.

Chiarito M, Mehran R, Gibson MC et al. · European heart journal · (2026) · View on PubMed ↗

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

This prospective multicenter single-group study evaluated 124I-evuzamitide positron emission tomography/computed tomography (PET/CT) for diagnosing cardiac amyloidosis across multiple amyloid types and organs in participants recruited from 18 US centers. The key diagnostic performance results (sensitivity and specificity) were generated for 124I-evuzamitide PET/CT as a noninvasive test for cardiac involvement. If validated, this technique could expand amyloidosis imaging beyond transthyretin-only approaches and improve diagnostic accuracy for patients with suspected cardiac amyloidosis.

Dorbala S, Maurer MS, Cuddy SAM et al. · JAMA · (2026) · View on PubMed ↗

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

This prespecified FIND-CKD subgroup analysis studied finerenone versus placebo in adults with hypertensive nephropathy (eGFR 25 to <90 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio 200 to 3500 mg/g) without diabetes. Finerenone reduced kidney function decline compared with placebo while assessing safety in this investigator-reported hypertensive nephropathy subgroup. Clinically, this supports mineralocorticoid receptor antagonism with finerenone as a kidney-protective option for hypertensive CKD patients beyond diabetic populations.

Heerspink HJL, Beernink JM, Agarwal R et al. · European heart journal · (2026) · View on PubMed ↗ · Free PDF ↗

Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant: The ACASA-TAVI Randomized Clinical Trial.

The ACASA-TAVI randomized clinical trial studied factor Xa inhibitor non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy versus acetylsalicylic acid (ASA) monotherapy after transcatheter aortic valve implantation (TAVI) in 360 participants aged 65 to 80 years. The trial compared safety and efficacy of the two post-TAVI antithrombotic strategies in an open-label design. If NOAC monotherapy proves noninferior or superior, it could simplify post-TAVI regimens and reduce bleeding risk relative to antiplatelet-only strategies.

Dodgson CS, Herstad J, Kløve SF et al. · JAMA · (2026) · View on PubMed ↗

Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.

This randomized clinical trial studied whether routine referral of patients with prostate cancer to a cardiovascular specialist for a systematic risk-factor strategy improves cardiovascular outcomes and risk factor control versus usual care. The intervention was delivered across 55 sites in 8 countries, targeting patients diagnosed with prostate cancer within the prior 12 months. The results are significant for integrating cardio-oncology care pathways to reduce cardiovascular morbidity in a high-risk cancer population.

Leong DP, Higano C, Cano Garcia C et al. · JAMA internal medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Lpb. plantarum inhalation powders for the reduction of lung inflammation and S. aureus growth control in non-CF bronchiectasis.

This study investigated inhaled Lpb. plantarum (lactic acid bacteria) powders for reducing lung inflammation and controlling Staphylococcus aureus growth in non-cystic fibrosis (non-CF) bronchiectasis using spray-dried inhalation formulations. The key findings focused on in vitro effects of two powder compositions (with and without the prebiotic raffinose) on inflammatory responses and S. aureus growth. If translatable, this dual-action probiotic inhalation approach could offer a microbiome-targeted therapy addressing both infection and inflammation in bronchiectasis.

Glieca S, Tambassi M, Schianchi C et al. · Expert opinion on drug delivery · (2026) · View on PubMed ↗

Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a long-term follow-up of the randomized RIVETING trial.

This long-term follow-up of the randomized RIVETING phase 3b/4 trial studied dose reduction of tofacitinib in ulcerative colitis patients in stable remission, comparing tofacitinib 5 mg twice daily (BID) versus continuing 10 mg BID. The key outcome was whether patients maintained remission/efficacy and safety after stepping down the Janus kinase inhibitor dose over extended follow-up. This is clinically important for optimizing long-term balance between disease control and adverse effects in patients who achieve remission on higher-dose tofacitinib.

Rubin DT, Panés J, Torres J et al. · Crohn’s & colitis 360 · (2026) · View on PubMed ↗ · Free PDF ↗

Effects of Chronic Pain Medications on Cardiovascular Health: A Narrative Review.

This narrative review synthesized evidence on how commonly used chronic pain medications affect cardiovascular health, focusing on drug classes such as NSAIDs and acetaminophen and their cardiovascular risks. The key finding was that multiple analgesic options can influence cardiovascular outcomes through known or proposed cardiovascular side effects, potentially increasing major adverse cardiac and cerebrovascular events. The review is significant for clinicians weighing analgesic selection in patients at cardiovascular risk and for guiding safer pain management strategies.

Kent A, Toubasi AYM, Myles A et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Safety and Efficacy of Remimazolam Combined with Esketamine for Anesthesia in Elderly Patients Undergoing ERCP: A Randomized Controlled Trial.

This randomized controlled trial studied remimazolam combined with esketamine versus propofol-fentanyl for anesthesia in elderly patients (age 60–80) undergoing ERCP, using standardized nasopharyngeal airway-assisted respiratory management in both groups. The key finding compared safety and efficacy outcomes between the two anesthetic regimens in a population particularly vulnerable to sedation-related respiratory and circulatory adverse events. Results could inform anesthetic choice for ERCP in older adults to minimize adverse events while maintaining procedural effectiveness.

Yu Y, Wang J, Zhang Q et al. · Drug design, development and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Butyrate Regulating Inflammatory Responses in Chronic Obstructive Pulmonary Disease via the Gut-Lung Axis.

This narrative review examined how butyrate regulates inflammatory responses in COPD through the gut-lung axis, integrating preclinical and limited clinical evidence. The key finding was that butyrate, a microbial short-chain fatty acid derived from dietary fiber fermentation, can modulate immune pathways that link intestinal homeostasis to pulmonary inflammation. This is scientifically significant because it supports butyrate-targeted or microbiome-based strategies as potential disease-modifying approaches for COPD beyond symptomatic therapy.

Liu Q, Fu Q, Sun C et al. · International journal of chronic obstructive pulmonary disease · (2026) · View on PubMed ↗ · Free PDF ↗

Pain Modulation, Inflammation-Regulatory Mechanisms, and Translational Boundaries of Evidence for Acupuncture-Related Therapies in Knee Osteoarthritis: A Structured Narrative Review.

This structured narrative review assessed acupuncture-related therapies for knee osteoarthritis, synthesizing clinical and preclinical evidence on pain modulation and inflammation-regulatory mechanisms. The review concludes that biological plausibility exists (e.g., modulation of inflammatory and pain pathways), but translational boundaries and heterogeneity across study designs limit definitive clinical interpretation. These findings support cautious, mechanism-informed use of acupuncture-related interventions as adjunctive options while highlighting the need for more rigorous, standardized trials to clarify who benefits and why.

Yan B, Gong W · Journal of pain research · (2026) · View on PubMed ↗ · Free PDF ↗

Prevalence of dysphagia and eosinophilic esophagitis in patients with inflammatory bowel disease or type 2 inflammation: a cross-sectional multicenter screening study.

This cross-sectional multicenter screening study evaluated the prevalence of dysphagia and underlying eosinophilic esophagitis (EoE) in patients with type 2 inflammatory diseases (asthma, rhinosinusitis with polyposis nasi, allergic rhinitis, atopic dermatitis, IgE-mediated food allergies) or inflammatory bowel disease (IBD). The key finding was that EoE and clinically relevant dysphagia were present at measurable rates in these populations, supporting an increased burden beyond the general population. Clinically, the results justify considering EoE evaluation (e.g., endoscopic assessment with biopsies) in selected IBD/type-2 patients presenting with dysphagia.

Bäuerle M, Maurer J, Pokryszka J et al. · Therapeutic advances in gastroenterology · (2026) · View on PubMed ↗ · Free PDF ↗

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

This narrative review examined the concept of GLP-1 microdosing—using very small doses of GLP-1 receptor agonist strategies—in relation to potential multisystem benefits. The review’s central finding is that, despite established efficacy of full-dose GLP-1 receptor agonists for diabetes and obesity, emerging microdosing approaches are being proposed to reduce cost and supply barriers while potentially preserving some therapeutic effects. Scientifically and clinically, it frames GLP-1 microdosing as a hypothesis-generating strategy that requires controlled trials to define efficacy, safety, and pharmacologic exposure thresholds.

Panlilio MA, Piserchio N, Hennessey M et al. · Cureus · (2026) · View on PubMed ↗ · Free PDF ↗

Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib.

This post hoc pooled analysis of the ADMIRAL and COMMODORE trials studied response kinetics in relapsed/refractory FLT3-mutated acute myeloid leukemia patients treated with gilteritinib monotherapy, focusing on timing of composite complete remission (CRc) relative to on-study hematopoietic stem cell transplantation (HSCT). The analysis found that among 166 patients achieving CRc before HSCT, 89.2% achieved CRc within 6 gilteritinib cycles, with 36.1% achieving CRc after cycle 2 and 71.7% after cycle 4, enabling classification into early responders (ERs) and later responders (LRs). These data are clinically significant because they refine expectations for when responses occur with gilteritinib in FLT3-mut+ R/R AML and may inform treatment monitoring and decision-making around HSCT.

Perl AE, Levis MJ, Wei AH et al. · Blood neoplasia · (2026) · View on PubMed ↗ · Free PDF ↗

Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.

This preclinical study investigated whether harnessing necroptosis through RIPK1 degradation can potentiate radio-immunotherapy in cervical cancer, using single-cell RNA sequencing to identify necroptosis/RIPK1 patterns and then testing a RIPK1 degrader in combination with radiotherapy. The key finding was that radiotherapy increased RIPK1 expression and that combining RT with LD4172/Hf (a hafnium-based nanoscale metal-organic framework loaded with the RIPK1 degrader LD4172) induced necroptosis and enhanced anti-tumor immune effects compared with RT alone. Scientifically, it supports a mechanism-based strategy to overcome low tumor immunogenicity in cervical cancer by coupling RT with targeted RIPK1 degradation.

Wu T, Lv B, Wang H et al. · Bioactive materials · (2027) · View on PubMed ↗ · Free PDF ↗

Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis evaluated treatment-related adverse events (TRAEs) from clinical trials of tarlatamab in small cell lung cancer (SCLC), focusing on tarlatamab monotherapy safety. The key finding is that tarlatamab—an anti–delta-like ligand 3 (DLL3) bispecific T-cell engager targeting CD3—produces a distinct toxicity profile consistent with T-cell engager mechanisms, warranting careful adverse-event management. Clinically, the synthesis helps clinicians anticipate and monitor specific TRAEs when using tarlatamab in SCLC patients.

Vitale E, Maistrello L, Rizzo A et al. · JTO clinical and research reports · (2026) · View on PubMed ↗ · Free PDF ↗

A transcriptomics-based computational drug repurposing pipeline identifies simvastatin and primaquine as therapeutics for endometriosis.

This transcriptomics-based computational drug repurposing pipeline identified simvastatin and primaquine as candidate therapeutics for endometriosis and then tested them in a rat model of endometriosis-associated pain. The key finding was that, using behavioral testing plus bulk RNA sequencing and differential expression analysis, these drugs showed therapeutic potential consistent with the pipeline’s transcriptomic predictions. The study is significant because it provides data-driven, mechanism-linked repurposing candidates that could expand limited endometriosis treatment options.

Oskotsky TT, Tang X, Arthurs E et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Reduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain.

This single-centre, randomized, open-label phase 2 pilot trial (BETAF-RED) studied reduced-frequency oral antiretroviral therapy in virologically suppressed adults with HIV-1, comparing a reduced-frequency regimen based on bictegravir, emtricitabine, and tenofovir alafenamide. The key finding was that reduced-frequency dosing could maintain virological suppression in selected participants, while also highlighting the importance of exposure thresholds and the role of the HIV reservoir (as assessed in the trial). Clinically, it informs whether lower-burden ART strategies using bictegravir/emtricitabine/tenofovir alafenamide are feasible for carefully selected suppressed patients.

Chivite I, Moraga E, Sempere A et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Form and function of actin impacts actin health and aging.

This study used genetic and pharmacologic perturbations of actin and actin-binding proteins to determine how actin structure/function affects lifespan and aging hallmarks in Caenorhabditis elegans. The key finding was that whole-animal and tissue-specific knockdown of actin and key ABPs (arx-2/Arp2/3, unc-60/cofilin, lev-11/tropomyosin) caused premature disruption of filament organization, reduced lifespan, and tissue-specific physiological defects, accompanied by an “aged” transcriptome signature. Scientifically, it establishes a causal link between actin cytoskeletal integrity and organismal aging phenotypes.

Averbukh M, Nelson HT, Wang T et al. · iScience · (2026) · View on PubMed ↗

DVE-1 is a telomere-binding protein and links the NuRD complex to telomere regulation in C. elegans.

This C. elegans study characterized DVE-1 as a telomere-binding protein that links the NuRD complex to telomere regulation. The key findings were that DVE-1 binds the single-stranded C-rich telomeric sequence in vitro, co-localizes with POT-1 at telomeres in vivo, and that RNAi knockdown of dve-1 reduced TERRA expression while enhancing telomeric chromatin compaction. These results are significant because they define a specific telomere regulatory pathway involving DVE-1 and NuRD-like chromatin control mechanisms in vivo.

Sluka J, Blake A, Podvalnaya N et al. · iScience · (2026) · View on PubMed ↗ · Free PDF ↗

Adrenomedullin system dysregulation predicts cardiogenic shock and mortality in acute coronary syndromes.

In the SPUM-ACS cohorts (4098 in Switzerland and 824 in France), this study measured adrenomedullin system components—ADM-Gly, PAM, and bio-ADM—to test whether they predict cardiogenic shock and 1-year mortality after acute coronary syndromes (ACS). Dysregulation of the ADM system components was associated with higher cardiogenic shock risk and increased 1-year mortality. Clinically, ADM-pathway biomarkers may help identify ACS patients at imminent risk of shock and death, enabling earlier escalation of care.

Wang Y, Danchin N, Simon T et al. · European heart journal · (2026) · 1 citations · View on PubMed ↗

Eriodictyol regulates LDHB to trigger mitophagy-mediated NLRP3 inflammasome inactivation as a therapeutic strategy for bone loss.

This study examined whether the natural compound eriodictyol (ERI) protects against bone loss by targeting lactate dehydrogenase B (LDHB) and modulating mitophagy and NLRP3 inflammasome signaling in models of osteoclast-driven bone resorption. ERI was identified as an LDHB inhibitor that enhances mitophagy to inactivate the NLRP3 inflammasome, thereby reducing inflammatory bone loss. These findings suggest an LDHB–mitophagy–NLRP3 axis as a mechanistic therapeutic strategy for treating bone loss.

Wang Y, Pu W, Su Y et al. · Pharmacological research · (2026) · View on PubMed ↗ · Free PDF ↗

The complement system in the pathophysiology and treatment of depression: From synaptic pruning to pharmacological targeting.

This review analyzed evidence linking the complement system—particularly the C1q–C3–CR3 synaptic pruning axis and the anaphylatoxin receptors C3aR and C5aR—to depression pathophysiology and pharmacological targeting, integrating genetic and preclinical pharmacology data. It highlights that while preclinical studies implicate complement-mediated, region-dependent synaptic and neuroinflammatory changes, direct causal evidence in patients is still lacking. The work supports complement components (C3, C3aR, C1q) as mechanistically defined immune targets for next-generation depression therapies pending stronger clinical validation.

Song JY, Zhang ZQ, Lin TC et al. · Pharmacological research · (2026) · View on PubMed ↗ · Free PDF ↗

Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial.

This international, pragmatic, stepped-wedge, cluster-randomised, controlled trial evaluated the safety and efficacy of implementing the guideline-recommended 0/1 hour high-sensitivity cardiac troponin pathway versus the 0/3 hour pathway in emergency departments not yet using the newer strategy. It enrolled consecutive adults with acute non-traumatic chest discomfort and suspected myocardial infarction across 19 hospitals in ten countries. If the 0/1 hour pathway is safe and effective, it could improve ED throughput and earlier rule-in/rule-out of myocardial infarction while maintaining patient safety.

Boeddinghaus J, Bima P, Crisanti L et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Autochthonous chikungunya virus outbreak in Verona province, Italy, 2025.

This report studied an autochthonous chikungunya virus (CHIKV) outbreak in Verona province, Veneto, Italy, in 2025 using integrated epidemiological, virological, and entomological investigations. Following a surveillance protocol for early detection after an index case notification, the investigators characterized local transmission consistent with mosquito-borne spread in a temperate European setting. The findings are important for public health preparedness by demonstrating that CHIKV can establish local transmission in Italy and highlighting the value of coordinated arbovirus surveillance.

Castilletti C, Ancillotti L, Mori A et al. · Journal of travel medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Real-World Outcomes of Baricitinib in Patients with Rheumatoid Arthritis: A Two-Year Observational Study of Overall and Difficult-to-Treat Patients in Japan.

This two-year observational study evaluated real-world outcomes of baricitinib in Japanese patients with rheumatoid arthritis (RA), including difficult-to-treat (D2T) patients, stratified by prior b/tsDMARD use and baseline CDAI. Baricitinib showed effectiveness with analyses of time-to-discontinuation and time to low disease activity (LDA) or remission, using logistic regression adjusted for demographic and clinical variables. The results are clinically significant for guiding long-term treatment expectations and retention in routine care, especially for patients with challenging disease profiles.

Ikeda K, Kojima T, Tsujimoto N et al. · Modern rheumatology · (2026) · View on PubMed ↗ · Free PDF ↗

Brain MRI Changes Following Continuous Positive Airway Pressure Therapy in Adults with Obstructive Sleep Apnea: A Systematic Review.

This systematic review studied whether continuous positive airway pressure (CPAP) therapy reverses brain MRI abnormalities in adults with obstructive sleep apnea (OSA) by synthesizing longitudinal pre- and post-CPAP MRI evidence. It evaluated changes across structural, microstructural, functional, vascular, and metabolic brain domains using studies identified through database searches up to December 2025. The significance lies in clarifying whether CPAP produces measurable neuroimaging improvements, which could support CPAP’s role in mitigating OSA-associated brain injury.

Jalali M, Jalalvandi M, Tahmasebzadeh A et al. · Sleep · (2026) · View on PubMed ↗

Axonal pathology and impaired axo-glial crosstalk as early drivers of neurodegeneration.

This article reviewed evidence that axonal pathology and impaired axo-glial crosstalk can act as early drivers of neurodegeneration across diseases such as multiple sclerosis, Alzheimer’s disease, and frontotemporal dementia–amyotrophic lateral sclerosis spectrum. It emphasizes that axonal dysfunction (e.g., transport and cytoskeletal/trafficking defects) may not only follow somatic neuronal loss but could actively contribute to disease progression. The scientific significance is that targeting axon–glia communication and axonal maintenance pathways may offer earlier intervention points than strategies focused solely on neuronal survival.

Bues B, Sasmita AO, Mao S et al. · Neural regeneration research · (2026) · View on PubMed ↗

An Epstein-Barr virus-encoded snoRNA directs 2’-O-methylation of human rRNAs to control translation and the viral lytic switch.

This study investigated an Epstein-Barr virus (EBV)–encoded small nucleolar RNA, v-snoRNA1, and its role in controlling translation and the viral lytic switch. It showed that v-snoRNA1 directs 2’-O-methylation of human rRNAs at 18S-C621 and 28S-U1760, impairing 18S rRNA maturation, reducing translational fidelity/output, and slowing cellular proliferation; a v-snoRNA1 deletion virus (Δv-snoRNA1) increased protein synthesis and proliferation. These findings are significant because they reveal a specific viral RNA-guided rRNA modification mechanism that EBV uses to balance latency and lytic replication.

Dan Y, Jády BE, Halperin Y et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence: The ADHERE-ASCVD Randomized Clinical Trial.

The ADHERE-ASCVD randomized clinical trial studied whether an adaptive, sequential digital outreach program improves short-term statin refill compared with usual communication among adults with established atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk who recently had low statin adherence. The key finding is that adaptive digital outreach increased statin refills relative to usual communication in this health system-embedded pragmatic trial. Clinically, this provides evidence for scalable, behaviorally targeted digital interventions to improve medication adherence and reduce preventable cardiovascular events.

Bhatt AS, Liu VX, Sun B et al. · JAMA · (2026) · View on PubMed ↗

Non-Oncology Biomarkers in Precision Medicine: A Narrative Review.

This narrative review examined the role of biomarkers in non-oncology precision medicine across cardiovascular, renal, neurological, metabolic, and respiratory diseases, covering diagnostic, prognostic, predictive, surrogate, safety, and pharmacodynamic/response contexts. It highlights key biomarker examples such as high-sensitivity troponins and natriuretic peptides in cardiology and NGAL/KIM-1 in nephrology, emphasizing how regulatory framing differs from oncology. Scientifically and clinically, the review clarifies how biomarker evidence can be generated and positioned for non-oncology drug development and monitoring.

Livieratos A, Goea L, Das V et al. · Therapeutic innovation & regulatory science · (2026) · View on PubMed ↗

---

Antithrombotic strategies & device-related thrombosis

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

This pooled individual patient data analysis combined the ABYSS and SMART-DECISION randomized trials to assess non-inferiority of stopping versus continuing β-blockers in stable post–myocardial infarction patients with preserved left ventricular ejection fraction (LVEF ≥40%) and no heart failure. The study evaluated whether β-blocker discontinuation could be safely implemented in patients without a clear ongoing indication for β-blocker therapy. Clinically, the results could directly inform guideline-concordant de-escalation of long-term β-blocker treatment in selected stable coronary syndrome patients.

Silvain J, Choi KH, Monguillon V et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial.

The CAGUYAMA study investigated how concomitant factor VIII (FVIII) administration changes global coagulation potential in 100 people with hemophilia A without inhibitors who were receiving emicizumab prophylaxis. Concomitant FVIII produced measurable FVIII-induced shifts in global coagulation potential despite emicizumab’s baseline hemostatic activity, informing dosing during breakthrough bleeding and surgery. These findings support more rational FVIII add-on strategies for patients on emicizumab, potentially improving peri-event hemostasis while avoiding under- or over-dosing.

Takeyama M, Ogiwara K, Ozu N et al. · Research and practice in thrombosis and haemostasis · (2026) · View on PubMed ↗ · Free PDF ↗

---

Heart failure therapies & remodeling

SerpinA3 is an Endogenous TGF-β Receptor Antagonist that Attenuates Cardiac Fibroblast Activation and Fibrotic Remodeling.

This study investigated the role of SerpinA3 in cardiac remodeling using a transverse aortic constriction (TAC) mouse model and assessed effects of pharmacologic supplementation or genetic augmentation of SerpinA3 on fibroblast activation and fibrosis. SerpinA3 augmentation attenuated pressure-overload–induced cardiac dysfunction and fibrotic remodeling, including reduced cardiac fibroblast activation. The work positions SerpinA3 as a potential endogenous TGF-β receptor antagonist–based antifibrotic therapeutic target for preventing heart failure progression.

Wang H, Cui J, Huang C et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial.

The LUMINARA trial studied the oral relaxin family peptide receptor 1 agonist AZD5462 in adults with chronic heart failure randomized to 20 mg, 80 mg, or 360 mg once daily versus placebo, stratified by left ventricular ejection fraction (≤35% vs 41–55%). AZD5462 produced dose-dependent changes in cardiac remodeling measures, with primary results reported as changes in end-systolic volume. If confirmed in larger outcome studies, AZD5462 could represent a new oral mechanism targeting vascular tone/afterload and reverse remodeling in chronic HF.

Januzzi JL, Rosenmeier JB, Ely Pizzato P et al. · Circulation · (2026) · View on PubMed ↗ · Free PDF ↗

ALY688 Protects Against Myocardial Ischemia-Reperfusion Injury via Direct Effects and Rab8a-Dependent Extracellular Vesicles.

This study investigated ALY688, a synthetic adiponectin receptor agonist peptide, in a rat model of myocardial ischemia-reperfusion (IR) injury using intravenous administration during ischemia and continued subcutaneous dosing for 28 days. ALY688 reduced troponin-I levels, cardiomyocyte death, and infarct size while preserving cardiac function, and it restored autophagic flux via a Rab8a-dependent extracellular vesicle mechanism. These findings support ALY688 as a mechanistically targeted cardioprotective candidate that could translate into therapies to limit IR injury during reperfusion.

Sung HK, Tang J, Lei Y et al. · Journal of extracellular vesicles · (2026) · View on PubMed ↗ · Free PDF ↗

---

Atrial fibrillation ablation & rhythm management

Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial.

In the PVI-SHAM-AF randomized, double-blind, sham-controlled multicentre trial, adults (≥18 years) with symptomatic paroxysmal or persistent atrial fibrillation in Germany and Poland were assigned to catheter ablation (pulmonary vein isolation) or a sham procedure. The trial tested whether ablation improved atrial fibrillation–related quality of life more than sham treatment as the primary endpoint. If effective, this would strengthen the evidence base for catheter ablation as a symptom-relief strategy beyond placebo effects in symptomatic AF.

Wachter R, Haag P, Uhe T et al. · Lancet (London, England) · (2026) · View on PubMed ↗

Low-Voltage Ablation in Persistent Atrial Fibrillation: The IDEAL-AF Randomized Clinical Trial.

In the IDEAL-AF randomized clinical trial, patients with persistent atrial fibrillation and significant low-voltage zones underwent pulmonary vein isolation (PVI) alone or PVI plus adjunctive individualized low-voltage zone ablation at 5 Swedish ablation centers. The trial evaluated whether adding low-voltage zone ablation improved arrhythmia outcomes and health-related quality of life over 12 months compared with PVI alone. If positive, this would provide evidence to personalize ablation beyond standard PVI by targeting low-voltage substrate in persistent AF.

Paul Nordin A, Charitakis E, Carnlöf C et al. · JAMA · (2026) · View on PubMed ↗

---

Hypertension & blood pressure targets in cardiovascular disease

Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials.

This pooled participant-level analysis combined TOPCAT (Americas), PARAGON-HF, DELIVER, and FINEARTS-HF to evaluate whether time spent within systolic blood pressure (SBP) target ranges predicted cardiovascular outcomes in HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Greater time in the recommended BP range was associated with better subsequent cardiovascular outcomes across these trials. The study supports BP-control strategies in HFmrEF/HFpEF and helps refine the evidence for SBP targets in this population.

Lu H, Claggett BL, Ostrominski JW et al. · European journal of heart failure · (2026) · View on PubMed ↗

---

Cardiometabolic syndrome & global burden of disease

Associations of Illness Perception, Resignation Coping, and Social Support With Self-Regulatory Fatigue in Patients With Type 2 Diabetes: A Cross-Sectional Study.

This cross-sectional study of 302 adults with type 2 diabetes mellitus (T2DM) recruited from a tertiary hospital in China examined associations between illness perception, resignation coping, social support, and self-regulatory fatigue (SRF). The key finding was that resignation coping and social support were linked to SRF, with effects operating in the context of illness perception (including indirect pathways). These results suggest psychosocial targets—especially coping style and perceived support—may help reduce SRF in T2DM patients.

Liu Q, Zhou Y, Li B et al. · Nursing open · (2026) · View on PubMed ↗

The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023.

This Global Burden of Disease 2023 analysis studied trends from 1990–2023 in mortality and disability-adjusted life years (DALYs) for atherosclerotic cardiovascular disease, chronic kidney disease, type 2 diabetes, obesity, and metabolic dysfunction–associated steatotic liver disease across 204 countries and territories. The study quantified the multi-organ CKLM burden over time and stratified epidemiologic trends by age, sex, region, and sociodemographic index. These results provide a global evidence base for CKLM-targeted prevention and resource planning to reduce intertwined cardiometabolic and liver-kidney-cardiovascular outcomes.

Jayabaskaran J, Himan HR, Nagarajan S et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Clonal haematopoiesis and cardiovascular-kidney-metabolic syndrome: a cohort study.

This UK Biobank cohort study examined whether clonal haematopoiesis of indeterminate potential (CHIP)—including major gene-specific CHIP subtypes and large CHIP—predicts CKM (cardiovascular–kidney–metabolic) syndrome stage and progression. CHIP presence and specific gene-driven CHIP patterns were associated with CKM stage and progression to more advanced CKM stages. These findings link somatic hematopoietic mutations to systemic CKM risk, suggesting CHIP could be used for risk stratification and mechanistic insight into CKM syndrome.

Chang A, Li L, Ezzat D et al. · European heart journal · (2026) · View on PubMed ↗

---

Diabetes prevention & glucose-lowering strategies

The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.

This narrative review summarizes evidence for using sodium-glucose cotransporter 2 (SGLT2) inhibitors (“gliflozins”) to prevent progression from prediabetes to type 2 diabetes in adults. The key takeaway is that SGLT2 inhibitors are increasingly studied as pharmacologic options to delay or reduce incident T2DM risk, alongside established agents such as metformin, pioglitazone, acarbose, and GLP-1 receptor agonists. Clinically, it frames how SGLT2 inhibitors might fit into prevention strategies for high-risk prediabetes populations.

Owczarczyk-Durma AC, Blicharska M, Czupryniak L · Diabetes therapy : research, treatment and education of diabetes and related disorders · (2026) · View on PubMed ↗ · Free PDF ↗

---

Kidney disease & nephrology therapeutics

Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies.

This article reviewed translational barriers in diabetic kidney disease (DKD) drug development, focusing on target validation challenges and strategies to de-risk trials after repeated failures to improve hard kidney outcomes. It discusses how mechanistically rational agents have often failed to translate into durable clinical benefit despite biomarker signals, and it frames current disease-modifying standards (RAAS blockade, SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists) as context for why new approaches are needed. The review is significant for guiding more robust target selection, biomarker strategy, and trial design to reduce DKD translational failure.

Hu H, Hou S, Chen W et al. · Biochemical pharmacology · (2026) · View on PubMed ↗

---

Liver disease & bile acids

Bile Acid Profiles Define Disease-Specific Cholestatic States in Primary Sclerosing and Primary Biliary Cholangitis.

This study profiled circulating bile acids (BAs) in patients with primary sclerosing cholangitis (PSC, n=269) and primary biliary cholangitis (PBC, n=262) and compared them with matched controls to determine whether BA patterns define disease-specific cholestatic states. Distinct BA composition/conjugation and pool characteristics differentiated PSC from PBC and were associated with hepatic decompensation risk. The work supports BA profiling as a mechanistic biomarker approach to distinguish PSC vs PBC biology and potentially stratify patients by progression risk.

Juran BD, McCauley BM, Hu C et al. · Gastro hep advances · (2026) · View on PubMed ↗ · Free PDF ↗

Post-pancreatectomy Liver Injury After Mayo Clinic Class Ia Celiac Axis Resection: Illustration of This Newly Described Entity with Delayed Hepatic Artery Revascularization.

This case report described post-pancreatectomy liver injury after Mayo Clinic class Ia celiac axis resection in a 59-year-old patient with locally advanced pancreatic cancer who received neoadjuvant FOLFIRINOX. The patient developed delayed hepatic artery revascularization–related liver injury, illustrating a newly described complication entity. Awareness of this scenario can improve surgical planning and postoperative monitoring for hepatic ischemia risk after celiac axis resection.

Garnier J, Amabile P, Palen A et al. · Annals of surgical oncology · (2026) · View on PubMed ↗

Efficacy and Safety of Vonoprazan-Tetracycline Dual Therapy Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-analysis.

This systematic review and meta-analysis compared 14-day vonoprazan–tetracycline dual therapy (VT) versus bismuth-containing quadruple therapy (BQT) for Helicobacter pylori eradication, drawing on randomized controlled trials identified through database searches up to July 1, 2026. The key finding is the pooled assessment of relative efficacy and safety between these regimens for H. pylori eradication. Clinically, the comparison informs guideline-relevant selection of first-line eradication therapy, particularly where antibiotic resistance and tolerability are major constraints.

Jalal AA, Fatima SS, Wasio A et al. · The Annals of pharmacotherapy · (2026) · View on PubMed ↗

Serum HBsAg cannot distinguish cccDNA activity from integrated HBV DNA expression in chronic hepatitis B virus infection.

This study evaluated whether serum hepatitis B surface antigen (HBsAg) can distinguish covalently closed circular DNA (cccDNA) activity from integrated HBV DNA expression (iDNA) in chronic hepatitis B. Using intrahepatic HBsAg immunostaining, quantitative serum HBsAg (qHBsAg), and digital droplet PCR-based profiling of HBV DNA and RNA from liver biopsies, the authors found that serum HBsAg does not reliably differentiate cccDNA-driven transcription from iDNA-driven expression. This is significant for hepatitis B “functional cure” assessment, indicating that additional assays beyond serum HBsAg are needed to infer cccDNA activity.

Suslov A, Matter MS, Calabrese D et al. · Journal of hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

Decoding the Bile Acid-Mitochondria Axis: Implications for Disease Management and Therapeutic Opportunities.

This review synthesized mechanistic evidence for the bile acid–mitochondria axis, emphasizing how bile acids signal through FXR and TGR5 to regulate mitochondrial quality control, biogenesis, dynamics, and redox homeostasis. The key finding is the integrated pathway model linking FXR/TGR5 signaling to mitochondrial biogenesis (e.g., via PGC-1α and cAMP–PKA–CREB) and to mitochondrial fission/calcium homeostasis (e.g., via PKCδ/Drp1 and GRP75–MAMs), with implications for disease management. Therapeutically, it highlights potential opportunities to target bile acid receptors and downstream mitochondrial pathways to treat metabolic, inflammatory, and degenerative diseases.

Jia X, Zhang Z, Lin X et al. · Pharmacological research · (2026) · View on PubMed ↗ · Free PDF ↗

MiR-122 regulates liver tolerance.

This study examined the role of the liver-specific microRNA miR-122 in immune tolerance by using miR-122 knockout (KO) mice and comparing transcriptomic signatures with autoimmune hepatitis (AIH) patient data. miR-122 KO mice developed early liver inflammation and fibrosis (as early as two weeks), with an inverse relationship between miR-122 expression and inflammation/fibrosis. These findings establish miR-122 as a key regulator of liver immune tolerance and suggest that restoring miR-122 function could modulate inflammatory liver disease.

Gefen M, Layani S, Klahr E et al. · JHEP reports : innovation in hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Microbiome & metabolomics in disease and therapy

Baseline gut microbiome and metabolome profiles predict weight loss after a structured lifestyle intervention.

This study evaluated whether baseline gut microbiome and metabolome profiles predict weight loss and metabolic improvement after a one-year structured lifestyle intervention in 50 adults with obesity (mean BMI ~42 kg/m²). Baseline microbial and metabolomic signatures were associated with subsequent weight-loss success following the very low-calorie formula diet, transition, and maintenance phases. These results support using multi-omics baseline profiling to personalize lifestyle interventions and improve metabolic outcomes.

Seethaler B, Basrai M, Delzenne NM et al. · Microbiome · (2026) · View on PubMed ↗ · Free PDF ↗

The cold-water immersion recovery-adaptation paradox: Reconciling acute parasympathetic and analgesic benefits with chronic hypertrophy attenuation.

This narrative review studied cold-water immersion (CWI) as a post-exercise recovery modality in elite sport and clinical rehabilitation, focusing on how acute parasympathetic and analgesic benefits relate to chronic attenuation of skeletal-muscle hypertrophy. It concludes that while repeated CWI can improve short-term recovery markers (e.g., reduced soreness and faster parasympathetic reactivation), it can suppress molecular/cellular pathways required for resistance-training–induced hypertrophy across training mesocycles. The “paradox” is significant for designing recovery protocols that preserve performance and comfort without undermining long-term muscle adaptation.

Tornero-Aguilera JF, Lozano-Meca J, López-Moreno M et al. · Experimental physiology · (2026) · View on PubMed ↗ · Free PDF ↗

Host-to-Pathogen Transfer of Neutrophil Components via Extracellular Vesicles Shields Candida albicans From Immune Attack in Human Blood.

This study examined how neutrophil-derived extracellular vesicles (EVs) affect host defense against Candida albicans in human blood. It found that EVs enriched with antimicrobial proteins and neutrophil markers (including CD66b, CD45, CD63, and complement receptors CR1/CR3/CR4) bind C. albicans in a complement-dependent manner (partially inhibited by anti-CD11b, implicating CR3) and promote an immune-evasion state without impairing fungal growth. The work is significant because it identifies a specific EV-mediated pathway by which neutrophils can inadvertently shield C. albicans from immune attack, informing strategies to modulate EV–fungus interactions in candidemia.

Patitz JJ, Nieuwenhuizen NE, Solomatina A et al. · Journal of extracellular vesicles · (2026) · View on PubMed ↗ · Free PDF ↗

Gut Microbiota from Patients with Long COVID Persisting for 2 Years Result in Alterations in Mice that Resemble Post-COVID Symptoms.

The study profiled gut microbiota and metabolites from long COVID patients persisting for 2 years (n=11) versus healthy controls (n=11) using shotgun metagenomics and fecal liquid chromatography–mass spectrometry (LC-MS), and then tested causality by fecal microbiota transplantation into antibiotic-treated (ABx) mice. It found that long COVID-associated microbiota and metabolites produced mouse alterations resembling post-COVID symptoms, supported by histopathology and 16S rRNA sequencing after transplantation. This suggests that persistent gut microbial dysbiosis may contribute to long COVID pathophysiology and could inform microbiome-targeted interventions.

Zhang D, Chen C, Xie Y et al. · Probiotics and antimicrobial proteins · (2026) · View on PubMed ↗

---

Neurodegeneration & brain aging mechanisms

NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria.

Using “mutator” mitochondrial progeria mice, this study tested whether nicotinamide riboside (NR), an NAD+ precursor, prevents cardiomyopathy while assessing tissue-specific consequences. NR treatment prevented cardiomyopathy but caused divergent adverse effects in other tissues, including impaired erythroid maturation and worsened anemia due to disrupted heme biosynthesis and altered metabolic pathways. The findings highlight that NAD+ precursor therapy may require careful balancing of organ-specific benefits and toxicities in mitochondrial progeria.

Khan NA, Ahlqvist K, Pradhan S et al. · Cell reports · (2026) · View on PubMed ↗

GRAF1-dependent endocytotic processes and the Golgi apparatus contribute to previously unrecognized intermediate stages of early ciliogenesis.

This study examined early ciliogenesis in cells by defining GRAF1-dependent endocytotic processes and Golgi contributions to previously unrecognized intermediate stages of primary cilia formation. It showed that distal appendage vesicles and tubules fuse laterally to form a doughnut-shaped membrane structure, with Golgi and endocytotic pathways supplying membrane material during centripetal closure. These mechanistic insights refine the cellular model of how cilia membranes are built and may inform broader understanding of ciliopathies.

Schmidt KN, Buerger K, Maier O et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Associations between diet quality, epigenetic aging and epigenome in two population-based cohorts.

This study assessed how adherence to ten diet quality scores relates to epigenetic aging markers and genome-wide DNA methylation profiles in participants from the Rhineland Study, with validation in the EPIC-Potsdam cohort. The authors report minimal overlap between participants classified as adherent across different “healthy diet” scores and identify diet–methylation/aging associations that are not uniform across scores. These findings suggest that diet quality indices capture partly distinct biological effects, implying that epigenetic biomarkers may be sensitive to the specific dietary pattern rather than “healthy diet” broadly.

Tavares JF, Liu D, Talevi V et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

DNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression.

This work used global DNA methylation profiling in a cross-sectional and a longitudinal human meningioma cohort to identify epigenomic determinants of clinical heterogeneity and progression. The study identified a DNA hypermethylation signature correlated with clinical outcomes and enabling more accurate prognostication than prior meningioma classification systems, with emphasis on long-range epigenetic silencing of clustered protocadherin genes. Clinically, the methylation signature could improve risk stratification and guide management of meningioma patients likely to progress.

Merk DJ, Paßlack P, Surender S et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.

This randomized controlled trial evaluated dual antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome using potent P2Y12 inhibitors instead of the commonly used clopidogrel, alongside a direct oral anticoagulant (DOAC). The key finding (as framed in the abstract) is that the trial was designed to address concerns from prior studies/meta-analyses that dual therapy can increase ischemic events early after initiation, particularly with clopidogrel-related high on-treatment platelet reactivity. If effective, this strategy could refine early post-ACS antithrombotic regimens by improving platelet inhibition while maintaining bleeding safety compared with standard approaches.

Rizas KD, Mourouzis K, Rath D et al. · Nature medicine · (2026) · View on PubMed ↗ · Free PDF ↗

The Cognitive Effects of Creatine Supplementation in Older Adults and Preclinical Models of Dementia: A Scoping Review.

This scoping review mapped evidence on creatine supplementation and cognitive outcomes in older adults and in preclinical dementia models. The key finding is a structured overview of how creatine—via the phosphocreatine/ATP buffering system and proposed neuroprotective mechanisms—has been studied across dementia-relevant cognitive endpoints, while highlighting gaps in intervention characteristics and outcome reporting. The review supports creatine as a candidate metabolic intervention for dementia but underscores the need for more rigorous, dementia-specific clinical trials.

Whitford T, Donlon C, Pech A et al. · Ageing research reviews · (2026) · View on PubMed ↗

Mesenchymal drift in ciliopathy iPSC-derived RPE reveals a convergent pathogenic cell state.

The study generated induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) models from nine ciliopathy patients carrying mutations in BBS1, BBS10, BBS16, CEP290, LCA5, MYO7A, and PRPF31 to test whether downstream, mutation-agnostic pathways drive retinal defects. The authors report a “mesenchymal drift” phenotype and identify a convergent pathogenic cell state in ciliopathy iRPE that emerges despite different primary cilium gene defects. This supports a gene-agnostic therapeutic strategy targeting shared downstream mechanisms of ciliopathy-associated retinal degeneration rather than single-gene interventions.

Reichert D, Gul S, Ortolan D et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neuroinflammation, infection & CNS-related mechanisms

Gut microbiota and blood biomarkers as correlating factors in patients with postoperative delirium: analysis of three prospective observational studies.

This prospective observational study analyzed 491 patients aged ≥65 undergoing elective laminectomy or hip/knee replacement to determine how gut microbiota, the gut-derived metabolite indole-3-propionic acid (IPA), and plasma Tau protein levels relate to postoperative delirium. The study tested correlations among specific gut microbial features, IPA, and Tau phosphorylation/levels in patients with versus without postoperative delirium. The results support a bile acid–/microbiome–brain axis concept in delirium biology and could inform biomarker-driven prevention or stratification after surgery.

Song W, Singh S, Xiang W et al. · Molecular psychiatry · (2026) · View on PubMed ↗

289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.

This ENMC international workshop report synthesized emerging evidence on AAV-mediated gene therapy toxicities in neuromuscular disorders, focusing on adverse events observed after onasemnogene abeparvovec (Zolgensma) and delandistrogene moxeparvovec-rokl (Elevidys). The key output is a consensus-style framework for assessing and managing AAV-related toxicities affecting vital organs (including blood, liver, muscle, and heart) based on clinical trial and post-marketing experience. Scientifically and clinically, it provides practical guidance to improve monitoring and mitigation of serious AAV toxicities as gene therapy expands in neuromuscular care.

Orbach R, Gil Garzon MR, Büning H et al. · Neuromuscular disorders : NMD · (2026) · View on PubMed ↗

Heterogeneous Associations of Antidiabetic Medications with Cancer Prognosis: Evidence from 61 Studies with Over 1.1 Million Patients.

This systematic review and meta-analysis evaluated prognostic associations of seven classes of antidiabetic medications with cancer outcomes across 61 studies totaling over 1.1 million patients, focusing largely on populations with concomitant type 2 diabetes mellitus (T2DM). The key finding is a pooled, class-level comparison of cancer prognosis effects for antidiabetic drugs (including metformin and insulin among others) in observational and randomized evidence. These results are clinically relevant for risk stratification and for selecting glucose-lowering therapies in patients with cancer and T2DM.

Luo P, Ding Y, Huang W et al. · Pharmacological research · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy and safety of gabapentin for treatment of cough in idiopathic pulmonary fibrosis: a randomized, double-blinded, placebo-controlled clinical trial.

This randomized, double-blind, placebo-controlled clinical trial studied gabapentin in adults with idiopathic pulmonary fibrosis (IPF) who had chronic cough for more than 8 weeks and elevated cough severity by visual analog scale (VAS) at Tongji Hospital. The key finding reported in the abstract is that the trial was designed to determine whether gabapentin improves IPF-related cough and to assess its safety profile versus placebo. If effective, gabapentin would provide a mechanistically distinct, symptomatic treatment option for IPF-associated cough beyond limited current therapies.

Zhou Y, Ju X, Zhang Y et al. · Chest · (2026) · View on PubMed ↗

Does HIV-1 infection drive Alzheimer’s disease pathobiology?

This review examined whether HIV-1 infection and its persistent effects in the brain contribute to Alzheimer’s disease (AD) pathobiology in the context of HIV-associated neurocognitive disorders (HAND). It highlights that chronic microglial activation and neuroinflammation—driven by persistent viral reservoirs and low-level viral protein expression—can promote amyloid-β aggregation, impair clearance, and accelerate neurodegeneration. These mechanistic links suggest HIV-1 may increase AD risk and that targeting glial dysfunction/neuroinflammation could be clinically relevant for preventing or slowing AD-like pathology in treated people with HIV.

Etafo EO, Dutta D, Bhattarai S et al. · Neuroscience and biobehavioral reviews · (2026) · View on PubMed ↗

Long-term outcome after fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia: systematic review.

This systematic review studied long-term outcomes (≥1 year) after fetal endoscopic tracheal occlusion (FETO) for congenital diaphragmatic hernia (CDH) in infants, synthesizing evidence from multiple databases up to October 2025. The review assessed domains including growth/nutrition, neurodevelopment, audiology, cardiac, respiratory, gastrointestinal, and musculoskeletal outcomes using Cochrane risk-of-bias tools and the Newcastle–Ottawa scale. Clinically, the findings aim to clarify the durability and safety profile of FETO beyond infancy, informing counseling and follow-up strategies for children with CDH.

Shah S, Ruiz Roman R, Nicolaides KH · Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer therapeutics (immunotherapy, targeted therapy, and trials)

Multi-ancestry sequencing analysis in 293,141 participants identifies predisposition DNA repair genes associated with HCC risk.

This multi-ancestry sequencing study analyzed whole exome sequencing (WES) and whole genome sequencing (WGS) data from 2,594 hepatocellular carcinoma (HCC) cases and 290,547 cancer-free controls across diverse biobanks (including Penn Medicine BioBank, All of Us, Mayo Clinic, ESCALON, and the Million Veteran Program) to test whether rare germline variants in DNA repair genes associate with HCC risk. It identified predisposition DNA repair genes linked to increased HCC risk across ancestrally diverse populations. These results support incorporating germline DNA repair gene assessment into HCC risk stratification and potentially refining hereditary cancer screening beyond Lynch and BRCA1/2.

Garofalo AM, Chotiprasidhi P, Johnson JP et al. · JHEP reports : innovation in hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study.

This real-world, multicenter, prospective observational study protocol (RERUN) will evaluate trastuzumab deruxtecan (T-DXd), a HER2-targeting antibody-drug conjugate, in Chinese patients with HER2-mutant metastatic non-small cell lung cancer (NSCLC). The key aim is to generate real-world effectiveness and safety evidence for T-DXd in routine clinical practice in this population where such data are currently limited. If successful, the study will support more generalizable clinical decision-making and post-approval evidence generation for T-DXd in HER2-mutant metastatic NSCLC.

Duan J, Zhuo M, Su C et al. · Advances in therapy · (2026) · View on PubMed ↗

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

This report summarizes part C of the phase 2 SGN35-027 trial evaluating brentuximab vedotin plus nivolumab with chemotherapy (doxorubicin and dacarbazine; AN+AD) in nonbulky, early-stage classical Hodgkin lymphoma (cHL). The key findings reported include a very high objective response rate at end of treatment (96%) with high treatment completion (98% received all four cycles). These results are clinically significant because they suggest strong early efficacy and manageable feasibility for an immunotherapy–antibody-drug conjugate–chemotherapy combination in early-stage cHL.

Abramson JS, Straus DJ, Bartlett NL et al. · Advances in therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Hemostatic single-fraction 8 Gy radiotherapy for tumor bleeding: a single-centre retrospective study.

This single-center retrospective study assessed hemostatic efficacy and rebleeding after single-fraction 8 Gy radiotherapy in patients with tumor bleeding treated between January 2020 and December 2024 (90 lesions). The key finding is that single-fraction 8 Gy RT achieved hemostasis with measurable rebleeding, and the analysis identified factors associated with both hemostatic success and subsequent rebleeding. Scientifically and clinically, the results help refine patient and lesion selection for short-course palliative radiotherapy to control tumor-related bleeding.

Makita K, Hirata H, Nakamura M et al. · Japanese journal of radiology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer mechanisms & tumor microenvironment

IFI27 and BAX are Essential for GSDME-Mediated Myeloma Cell Pyroptosis.

This mechanistic cancer biology study identified IFI27 as a driver of GSDME-mediated pyroptosis in multiple myeloma (MM) cells. IFI27 was upregulated in pyroptotic MM cells and overexpression triggered pyroptosis in MM cell lines and newly diagnosed MM cells in a GSDME-dependent manner, with mitochondrial impairment required for full pyroptotic induction. These findings implicate the IFI27–mitochondria–GSDME axis as a potential therapeutic vulnerability to induce pyroptosis in MM.

Cui Y, Sun Y, Liu Z et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

WTAP Transcriptional Suppression by KLF9 Drives Osteoclastogenesis via M6A-Mediated Regulation of CSF1R Signaling in Estrogen-Deficient Osteoporosis.

This study explored how WTAP (an m6A methyltransferase complex component) regulates osteoclastogenesis in estrogen-deficient osteoporosis through m6A-dependent control of CSF1R signaling. Myeloid-specific Wtap knockout worsened osteoclast formation and bone loss, and WTAP promoted m6A deposition on Csflr mRNA to enhance YTHDF2-mediated degradation and suppress CSF1R expression; KLF9 was identified as an upstream inducer of WTAP. The results connect KLF9–WTAP–m6A–YTHDF2–CSF1R regulation to osteoclast activation, suggesting epitranscriptomic modulation as a therapeutic direction.

Shen C, Liu X, Ge G et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗

DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling.

Using single-cell transcriptomics plus in vitro and in vivo experiments, this study investigated how DHCR24-positive tumor epithelial cells drive cisplatin resistance in bladder cancer. Cisplatin-resistant tumors showed hyperactivated cholesterol metabolism, and a chemoresistant epithelial subpopulation characterized by upregulated DHCR24 activated lipid raft–associated MAPK signaling. Targeting DHCR24/cholesterol metabolism or the lipid raft–MAPK axis may help overcome cisplatin resistance in advanced bladder cancer.

Zhao Y, Xing Z, Wang M et al. · Oncogene · (2026) · View on PubMed ↗

Cryo-EM structural analysis of liposome-reconstituted AcrB in the presence of substrates.

This study used cryo-electron microscopy (cryo-EM) to determine structures of the E. coli RND efflux transporter AcrB reconstituted into liposomes in the presence of the substrate doxorubicin (DOX). The authors observed both the functional LTO state and the resting LLL state on the same EM grid, indicating substrate-dependent conformational heterogeneity under liposome-reconstituted conditions. The structural snapshots provide new mechanistic insight into AcrB transport states that can inform strategies to overcome antimicrobial resistance.

Akisada S, Sakaguchi W, Nakano A et al. · Journal of structural biology · (2026) · View on PubMed ↗

SREBP-driven lipogenesis coupled with ferroptosis resistance as a therapeutic target in PTEN-loss extrahepatic cholangiocarcinoma.

This study investigated whether SREBP-driven lipogenesis coupled with ferroptosis resistance can be targeted therapeutically in PTEN-loss extrahepatic cholangiocarcinoma (eCCA) using clinically relevant genetically engineered mouse models. In CK19-CreERT-based models with biliary epithelial cell-specific PTEN deletion combined with additional oncogenic alterations (including TGFβR2 loss or Kras activation), the authors aimed to define a vulnerability that links lipid metabolism to ferroptosis escape. The work positions the SREBP–lipogenesis/ferroptosis-resistance axis as a potential actionable therapeutic strategy for PTEN-loss eCCA.

Hayata Y, Matsushita Y, Tempaku M et al. · JHEP reports : innovation in hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

This preclinical study tested whether exportin 1 (XPO1) inhibition improves the efficacy and durability of RAS-pathway targeted therapy in KRASG12D mutant pancreatic ductal adenocarcinoma (PDAC). Using KRASG12D inhibitor- and pan-RAS inhibitor-resistant PDAC cellular models, the authors evaluated sensitivity to the second-generation XPO1 inhibitor eltanexor (and assessed combination effects with KRAS-pathway inhibitors such as MRTX1133 and zoldonrasib). The results support XPO1 inhibition as a strategy to overcome adaptive resistance and extend response durability in KRAS-mutant PDAC.

Khan HY, Al Hallak MN, Aboukameel A et al. · Cancer letters · (2026) · View on PubMed ↗

---

---

Generated automatically on August 31, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.